|Bid||92.78 x 200|
|Ask||92.85 x 200|
|Day's Range||92.20 - 94.75|
|52 Week Range||78.42 - 100.51|
|PE Ratio (TTM)||-85.88|
|Earnings Date||Oct 26, 2017|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||112.59|
What: BioMarin Pharmaceutical, Inc., a world leader in developing and commercializing innovative biopharmaceuticals for rare diseases driven by genetic causes, will visit the Nasdaq MarketSite in Times ...
Spark's positive vote by an FDA committee could be a boon for other drugmakers working on gene therapies including Audentes, BioMarin and Ultragenyx.
SAN RAFAEL, Calif. , Oct. 11, 2017 /PRNewswire/ -- Key program updates will include the following: BMN 270 gene therapy for hemophilia A: 4e13 dose and Phase 3 Study Design Vosoritide for achondroplasia: ...
SAN RAFAEL, Calif. , Oct. 10, 2017 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Jean-Jacques Bienaimé, Chairman and Chief Executive Officer of BioMarin, will host a ...
Of the 29 analysts covering Biogen (BIIB) in October 2017, six analysts recommended a “strong buy,” 12 analysts recommended a “buy,” and 11 analysts recommended a “hold.” Biogen didn't receive any “sell” ...
In August 2017, the EC (European Commission) approved the label expansion of Alexion Pharmaceuticals' (ALXN) Soliris.
SAN RAFAEL, Calif. , Oct. 3, 2017 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN), a global leader in providing therapies for rare genetic diseases, today announced the appointment of former ...